The Lancet publication provides strong peer-reviewed validation of ATEV's clinical benefits, supporting the upcoming sBLA submission. Traders should monitor for sBLA acceptance and potential FDA decision timeline in H2 2026/H1 2027, which could catalyze a major label expansion and revenue inflection.
Price Chart
Executive Summary
Humacyte announced publication of one-year Phase 3 V007 trial results in The Lancet Digital Health, showing ATEV superiority over autogenous fistula for hemodialysis access, particularly in women and men with obesity/diabetes. This peer-reviewed validation complements the recent V012 Phase 3 success in female patients, supporting a planned sBLA submission in H2 2026 to expand the Symvess label for AV access.
Key Facts
- V007 Phase 3 one-year results published in The Lancet Digital Health, showing ATEV superiority over autogenous AV fistula for hemodialysis access
- Benefits highlighted for all female patients and male patients with obesity and diabetes — groups with higher AVF failure rates
- V012 Phase 3 study (female patients) met primary superiority endpoint; sBLA submission planned in H2 2026 to expand Symvess label for AV access
- ATEV already FDA-approved for extremity vascular trauma indication (December 2024)
- ATEV for AV access has RMAT and Fast Track designations from FDA
Financial Impact
No financial figures provided in the release; potential label expansion to AV access for hemodialysis could significantly expand addressable market beyond current trauma indication
Risk Factors
- sBLA submission and FDA approval are not guaranteed; regulatory risks remain
- Commercial adoption of ATEV for AV access depends on reimbursement and surgeon adoption
- Competition from existing AV access options and other bioengineered vessels
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3347583 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | Press Release | $0.4400 | awaiting T+60 | — | $0.4010 (−8.86%) |
Aug 19, 2026 9w ago | Press Release | $0.7349 | awaiting T+60 | — | $0.4010 (−45.43%) |
Aug 12, 2026 10w ago | 8-K | $0.6650 | awaiting T+60 | — | $0.4010 (−39.70%) |
Aug 12, 2026 10w ago | Press Release | $0.6650 | awaiting T+60 | — | $0.4010 (−39.70%) |
Aug 7, 2026 11w ago | Press Release | $0.7180 | awaiting T+60 | — | $0.4010 (−44.15%) |
Jun 12, 2026 19w ago | Institutional Cluster | $1.06 $0.5790 | ▼ −45.12% | ▼ −47.90% | $0.4010 (−61.99%) |
Jun 11, 2026 19w ago | 8-K | $1.06 $0.5790 | ▲ +45.12% | ▲ +47.90% | $0.4010 (+61.99%) |
Jun 10, 2026 19w ago | Press Release | $1.08 $0.5949 | ▲ +44.92% | ▲ +48.74% | $0.4010 (+62.87%) |
Jun 10, 2026 19w ago | Press Release | $1.08 $0.5949 | ▲ +44.92% | ▲ +48.74% | $0.4010 (+62.87%) |
Jun 10, 2026 19w ago | Press Release | $1.08 $0.5949 | ▼ −44.92% | ▼ −48.74% | $0.4010 (−62.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers